Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

The CARINAE study in Spain evaluated real-world outcomes of transplant-ineligible, newly diagnosed multiple myeloma (TIE-NDMM) patients treated with standard regimens without daratumumab (Group A) versus those receiving the DVMP regimen (daratumumab, bortezomib, melphalan, prednisone). Results showed the DVMP group had a higher 36-month progression-free survival rate (52.9% vs. 31.7%) and a lower rate of disease progression or death (36.8% vs. 67.3%) compared to Group A, supporting daratumumab’s effectiveness in frontline therapy.